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Abstract
Rationale: The hemodynamic effects of adaptive servoventilation (ASV) in patients with pulmonary hypertension
(PH) are unknown.
Methods: A series of clinically stable patients with pre- or post-capillary PH underwent ASV therapy (endexpiratory
positive airway pressure support 12–14 cm H2O, pressure support 4–10 cm H2O) during right heart catheterization.
Hemodynamics were measured at rest, at the end of a 15-min episode of ASV therapy, and 15 min after ASV
completion. Hemodynamic variables included heart rate, blood pressure, right atrial pressure (RAP), mean
pulmonary artery pressure (PAPm), pulmonary arterial wedge pressure (PAWP), cardiac output and pulmonary
vascular resistance (PVR).
Results: The study enrolled 33 patients; 12 patients with post-capillary PH due to heart failure with preserved
ejection fraction, and 21 patients with pre-capillary PH due to pulmonary arterial hypertension (n = 8) or chronic
thromboembolic pulmonary hypertension (n = 13). ASV was well tolerated by all patients and resulted in reductions
in systolic blood pressure (−8 mmHg, p = 0.01), PAPm (−5 mmHg, p <0.001) and PVR (−10 %, p = 0.01). Right and
left filling pressure increased, while the cardiac output decreased (−0.4 L/min; p < 0.001). The hemodynamic effects
of ASV were similar in both patient populations.
Conclusions: ASV had moderate hemodynamic effects in patients with PH of various origins, most importantly a
decline in systolic blood pressure, PAPm and cardiac output. ASV was safe and well tolerated during this short-term
study, but the observed drop in blood pressure and cardiac output may be of concern if ASV is applied in patients
with advanced PH and severely impaired right ventricular function.
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Introduction
Pulmonary hypertension (PH) is defined by a mean pul-
monary artery pressure (PAPm) ≥25 mmHg at rest. De-
pending on the level of the pulmonary artery wedge
pressure (PAWP), PH is divided into pre-capillary and
post-capillary forms, the former encountered in patients
with pulmonary arterial hypertension (PAH), chronic
thromboembolic pulmonary hypertension (CTEPH), or
PH due to lung disease; the latter in patients with left
heart disease such as heart failure with preserved ejec-
tion fraction (HFpEF) [1, 2].
Although some forms of PH may occur in young pa-
tients, the majority of patients with PH is in an advanced
age and often presents with co-morbidities such lung dis-
ease, left heart disease, obesity and sleep-related breathing
disorders. Obstructive or central sleep apnea has been
found in about one fourth of patients with pre-capillary
PH [3]. In addition, hypocapnic respiratory failure and
nocturnal period breathing are occasionally found in
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patients with PH [4, 5]. Moreover, these patients are at
risk of developing acute respiratory failure due to decom-
pensation of their underlying illness or due to intercurrent
diseases, such as pneumonia. Hence, in some of these pa-
tients, noninvasive ventilation (NIV) may be applied, ei-
ther as acute or long-term therapeutic intervention.
In patients with chronic left heart failure application
of continuous positive airway pressure (CPAP) or NIV
reduced pulmonary congestion and left ventricular pre-
load by increasing intrathoracic pressure and by redu-
cing afterload via reduction of transmural wall pressure.
Cardiac index remained stable or increased [6–8]. One
form of NIV is adaptive servoventilation (ASV), an auto-
matic bi-level positive airway pressure therapy with
anticyclical adaption of pressure support [9]. In patients
with chronic left heart failure, ASV did suppress noctur-
nal apneic and hypopneic events and had a positive
impact on cardiopulmonary function and cardiac remod-
eling [9–11]. However, the patients included in these
studies did not suffer from severe PH and it is possible
that the administration of positive pressure breathing
could have deleterious hemodynamic effects in such pa-
tients. Therefore, we evaluated the acute hemodynamic
effects of NIV in patients with pre-capillary or post-
capillary PH during right heart catheterization.
Methods
Patients
Patients admitted to our hospital for diagnostic work-up
or follow-up assessment of pulmonary hypertension were
invited to participate in this study. Patients with PAH,
CTEPH and PH-HFpEF according to current diagnostic
criteria were eligible. Patients with PH due to lung disease
were excluded as were patients already receiving noninva-
sive ventilation for other reasons.
All patients provided written informed consent and
the study was approved by the local ethics committee of
Hannover Medical School institutional review board
(Ethikkommission Medizinische Hochschule Hannover).
Right heart catheterization
Right heart catheterizations were performed via a jugular
approach following a standardized protocol. The pres-
sure transducer was zeroed at the mid-thoracic level
and pressure readings were done at end-expiration [2].
Measurement included right atrial pressure, PAPm,
PAWP and mixed venous oxygen saturation. Cardiac out-
put was measured by thermodilution with the reported
value being the average of at least three recordings with
less than 10 % variation. Pulmonary vascular resistance
was calculated according to standard formula. Baseline
measurements were made after a 15 min resting period
following catheter insertion. Intervention measurements
were made at the end of a 15-min ASV period, and post-
intervention (recovery) measurements were made after
another 15 min of rest and unsupported breathing.
Capillary and mixed-venous blood gas analyses
Experienced technicians obtained arterialized capillary
blood gases from earlobes. Mixed-venous blood was ob-
tained from the pulmonary arteries during right heart
catheterization. The blood samples were analyzed without
delay using a standard device (Radiometer, Copenhagen).
Adaptive servo ventilation
After individual mask fitting, ASV was initiated during a
15 min period using PaceWave™ modus with a standard-
ized protocol of pressure support level titration under
continuous blood pressure monitoring (Carescape V100).
Starting at 4 cm H2O, the minimum end-expiratory pres-
sure (EPAP) was increased every 5 min by 4 cm H2O up
to a maximum of 12 cm H2O, while maximum EPAP
(14 cm H2O), maximum pressure support (10 cm H2O),
and minimum pressure support (4 cm H2O) were kept
stable. Individual maximum tolerable pressure support
levels were then applied during right heart catheterization.
In patients receiving oxygen therapy, the flow of oxygen
was kept constant throughout the procedure.
Statistical analysis
Data are shown as mean ± standard deviation (SD). For
comparison of the two patient populations, Fisher’s exact
test, Chi-square test and two-sided paired t-test were
used as appropriate. Comparisons between baseline and
intervention were made with two-sided paired t-test.
Pearson correlation analysis was performed to assess
changes in right and left sided filling pressures and
changes in cardiac output. P-values <0.05 were consid-
ered statistically significant.
Results
The study enrolled 33 patients, 21 with pre-capillary PH
(PAH, n = 8; CTEPH, n = 13) and 12 with post-capillary
PH associated with HFpEF. The demographics and base-
line characteristics of the patients are shown in Table 1.
None of the patients had a history of sleep-related
breathing disorders. All patients were awake during the
procedures and periodic breathing was not observed in
any of these patients during the study.
Compared to patients with pre-capillary PH, patients
with post-capillary PH tended to be older and had a
higher body mass index. The patients in both cohorts
suffered from severe PH with an average PAPm of 46
and 43 mmHg, and a reduced cardiac index of 2.2 and
2.3 L/min/m2, respectively.
Familiarization with ASV on the day before right heart
catheterization was associated with a significant drop of
systolic blood pressure (prior to ASV therapy 131 ±
21 mmHg versus ASV therapy with maximum EPAP of
12 mmHg 122 ± 20 mmHg, p = 0.01) while diastolic blood
pressure (73 ± 12 mmHg vs. 73 ± 12 mmHg, p = n.s.) and
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mean arterial blood pressure (90 ± 20 mmHg versus 89 ±
13 mmHg, p = n.s.) remained unchanged. Clinically, ther-
apy initiation was uneventful and all patients tolerated the
procedure without any side effects.
The individual maximum tolerable pressure settings
were then applied the next day during right heart
catheterization without causing adverse events. Twenty-
nine patients (88 %) were ventilated at the highest-
pressure settings (maximum EPAP 14 cmH2O, maximum
pressure support 10 cmH2O). Hemodynamic effects have
been summarized in Table 2. There was an average decline
in systolic blood pressure by 8 mmHg (p = 0.01; Fig. 1)
while the diastolic blood pressure didn’t change signifi-
cantly (p = 0.40). The cardiac filling pressures increased
(right atrial pressure +2.4 mmHg and PAWP+ 3.6 mmHg;
both p-values < 0.0001). PAPm decreased by 5 mmHg (p <
0.0001), PVR decreased by 10 % (68 dyn · s · cm−5; p =
0.013) and cardiac output decreased by 0.4 L/min (p <
0.0001). The individual changes in cardiac output are
depicted in Fig. 2, which shows that the drop in cardiac
output was less consistent in patients with post-capillary
PH than in pre-capillary PH. The stroke volume did not
change significantly (p = 0.41), while the heart rate de-
clined by 7 beats per minute (p < 0.0001). There was no
correlation between the change in PAWP and the change
in cardiac output (r = 0.147, p = 0.414). In contrast, the
change in cardiac output was inversely related to the
change in right atrial pressure (r = −0.414, p = 0.017).
The peripheral oxygen saturation increased by +4 %
(p < 0.0001), as did the mixed venous oxygen saturation
Table 1 Patient characteristics at baseline
All (n = 33) Pre-capillary PH (n = 21) Post-capillary PH (n = 12) p-value*
Age (years) 68 ± 13 64 ± 15 72 ± 8 0.14
Female (%) 55 57 50 0.52
Body mass index (kg/m2) 28 ± 6 26 ± 5 31 ± 6 0.03
NYHA II/III/IV (n) 2/29/2 2/18/1 0/11/1 0.31
6 min walking distance (m) 315 ± 135 327 ± 147 289 ± 130 0.46
Right atrial pressure (mmHg) 12 ± 4 11 ± 4 13 ± 4 0.2
Mean pulmonary artery pressure (mmHg) 45 ± 11 46 ± 13 43 ± 9 0.46
Pulmonary arterial wedge pressure (mmHg) 13 ± 5 10 ± 3 18 ± 3 <0.001
Cardiac output (L/min) 4.2 ± 1.3 4.1 ± 1.1 4.4 ± 1.7 0.49
Cardiac index (L/min/m2) 2.2 ± 0.6 2.2 ± 0.4 2.3 ± 0.8 0.52
Stroke volume (ml) 63 ± 19 62 ± 20 64 ± 17 0.77
Pulmonary vascular resistance (dyn · s · cm−5) 660 ± 340 754 ± 367 495 ± 177 0.03
Peripheral oxygen saturation (%) 93 ± 3 93 ± 3 94 ± 2 0.95
Mixed venous oxygen saturation (%) 64 ± 6 63 ± 6 64 ± 6 0.21
*Pre-capillary versus post-capillary pulmonary hypertension
Table 2 Hemodynamic response to adaptive servoventilation in patients with pulmonary hypertension (whole group, n = 33)
Baseline Intervention Recovery p*
Systolic blood pressure (mmHg) 123 ± 19 115 ± 18 124 ± 19 0.010
Diastolic blood pressure (mmHg) 67 ± 12 66 ± 11 69 ± 12 0.40
Heart rate (min−1) 70 ± 13 64 ± 13 67 ± 12 <0.001
Right atrial pressure (mmHg) 11 ± 4 13 ± 4 11 ± 5 <0.001
Mean pulmonary artery pressure (mmHg) 45 ± 11 40 ± 11 44 ± 10 <0.001
Pulmonary arterial wedge pressure (mmHg) 13 ± 5 17 ± 5 14 ± 5 <0.001
Cardiac output (L/min) 4.2 ± 1.3 3.8 ± 1.2 4.2 ± 1.3 <0.001
Cardiac index (L/min/m2) 2.2 ± 0.6 2.0 ± 0.5 2.2 ± 0.5 <0.001
Stroke volume (ml/min) 63 ± 19 62 ± 20 64 ± 18 0.41
Pulmonary vascular resistance (dyn · s · cm−5) 660 ± 340 592 ± 353 644 ± 355 0.01
Peripheral oxygen saturation (%) 93 ± 3 96 ± 3 93 ± 4 <0.001
Mixed venous oxygen saturation (%) 64 ± 6 67 ± 6 62 ± 9 0.001
Mixed venous pCO2 (mmHg) 41 ± 5 38 ± 6 40 ± 7 <0.001
*Baseline versus intervention
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(+3 %; p = 0.0015). The mixed-venous pCO2 dropped by
an average of 4 mmHg (p < 0.0001). After 15 min of re-
covery, all values had returned to baseline (Table 2).
The results were essentially the same for patients with
pre-capillary and post-capillary PH, with the exception
of the less consistent change in cardiac output as stated
above (Tables 3 and 4).
Discussion
Our data show that ASV, at least when administered at
relatively high pressure levels, has hemodynamic conse-
quences in patients with PH including an increase in fill-
ing pressures, and declines in systolic blood pressure,
PAPm, PVR, and cardiac output.
The slight increases in filling pressures (RAP +2 mmHg,
PAWP +4 mmHg) were probably caused directly by the
increased intrathoracic pressure during ASV, and would
not be expected to be clinically relevant. However, our
data also show that right heart catheterization performed
during noninvasive ventilation may result in over inter-
pretation of the PAWP and could therefore lead to a mis-
classification of pre-capillary as post-capillary PH, at least
in some patients.
There was a considerable decline in PAPm and PVR.
The latter was caused by a drop in PAPm (−5 mmHg) and
an increase in PAWP (+4 mmHg). The drop in PAPm was
substantial and cannot be directly explained by increased
intrathoracic pressures during ASV, as this would have
caused the PAPm to increase as well. The drop in cardiac
output can explain part of the observed effect on PAPm to
some extent, although not entirely. Our data show that
ASV was associated with slight improvements in periph-
eral and mixed venous oxygenation as well as a fall in the
mixed venous pCO2, and it is possible that these effects
resulted in some pulmonary vasodilation.
Perhaps the potentially most relevant effects seen in
our study were the declines in systolic blood pressure
and cardiac output. It is not entirely clear why only the
systolic blood pressure decreased while the diastolic
blood pressure remained unchanged, especially as the
drop in cardiac output was not caused by a decline in
stroke volume but almost entirely by a drop in heart
rate. However, the observed effects on blood pressure
and heart rate were consistent with previous studies on
continuous positive airway pressure or NIV in patients
with left heart disease [12–15]. These effects may be ex-
plained, at least partly, by reduced cardiac sympathetic
nerve activity or increased parasympathetic nerve activ-
ity, which may result from stimulation of pulmonary
stretch receptors due to lung inflation [15, 16].
Nevertheless, the decline in cardiac output was a
somewhat unexpected finding, which has been described
Fig. 1 Systolic blood pressure at baseline and at the end of a 15-min period of adaptive servoventilation in patients with pre-capillary or
post-capillary pulmonary hypertension. In the entire group, there was a significant decline in systolic blood pressure (RR systolic) by 8 mmHg
(p = 0.01). In patients with pre-capillary pulmonary hypertension (PH), the systolic blood pressure dropped by 6 mmHg (p = 0.087); in patients with
post-capillary PH, it dropped by 11 mmHg (p = 0.07)
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with the administration of high pressure during NIV in
healthy individuals [17, 18] and in patients with chronic
obstructive pulmonary disease [19], but not in most
studies addressing the use of NIV patients with left heart
disease [7, 8, 11]. One exception was a study by Philip-
Joet et al. that reported a decrease in cardiac output
during administration of NIV in patients with left heart
disease and a low PAWP [20]. This observation, how-
ever, is not fully in line with the results of our study as
we did observe a decline in cardiac output in some pa-
tients with a PAWP >15 mmHg, albeit less consistent
than in patients with pre-capillary PH. Hence, the effects
Table 3 Hemodynamic response to adaptive servoventilation in patients with pre-capillary pulmonary hypertension (n = 21)
Baseline Intervention Recovery p*
Systolic blood pressure (mmHg) 117 ± 18 111 ± 13 119 ± 16 0.087
Diastolic blood pressure (mmHg) 65 ± 14 65 ± 9 68 ± 11 0.971
Heart rate (min−1) 69 ± 10 63 ± 11 66 ± 10 <0.001
Right atrial pressure (mmHg) 11 ± 4 13 ± 4 11 ± 5 0.002
Mean pulmonary artery pressure (mmHg) 46 ± 13 42 ± 12 44 ± 11 0.003
Pulmonary arterial wedge pressure (mmHg) 10 ± 3 15 ± 4 11 ± 3 <0.001
Cardiac output (l/min) 4.1 ± 1.1 3.6 ± 1.2 4.2 ± 1.3 0.001
Cardiac index (L/min/m2) 2.2 ± 0.4 1.9 ± 0.4 2.2 ± 0.4 <0.001
Stroke volume (ml/min) 62 ± 20 59 ± 20 63 ± 20 0.15
Pulmonary vascular resistance (dyn · s · cm−5) 754 ± 367 711 ± 372 750 ± 395 0.20
Peripheral oxygen saturation (%) 93 ± 2 97 ± 4 93 ± 3 <0.001
Mixed venous oxygen saturation (%) 65 ± 6 68 ± 6 62 ± 10 0.022
Mixed venous pCO2 (mmHg) 41 ± 5 37 ± 6 39 ± 8 0.001
*Baseline versus intervention
Fig. 2 Cardiac output (CO) at baseline and at the end of a 15-min period of adaptive servoventilation in patients with pre-capillary or post-capillary
pulmonary hypertension. In the entire group, cardiac output decreased by 0.4 L/min (p < 0.0001). In patients with pre-capillary pulmonary hypertension
(PH), cardiac output decreased by 0.5 L/min (p = 0.001). In patients with post-capillary pulmonary hypertension (PH), cardiac output decreased non-
significantly by 0.3 L/min (p = 0.11)
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of ASV on cardiac output seem to be less predictable in
patients with post-capillary PH than in patients with
pre-capillary PH, were a drop in cardiac output was a
very consistent finding. The changes in cardiac output
did not correlate with the changes in PAWP but there
was an inverse correlation between the changes in car-
diac output and the changes in right atrial pressure, pos-
sibly indicating additional strain on the right ventricle
induced by ASV.
ASV was well tolerated in all of our patients, both at
the familiarization day as well as during right heart
catheterization. There were no side effects and none of
the patients reported any discomfort, except for what was
caused by the facemask. Of note, all of our patients were
clinically and hemodynamically stable. We cannot con-
clude from our data that ASV would also be safe if applied
to patients with severe PH, right-sided heart failure and a
low blood pressure. On the first glimpse, the drop in
PAPm seems re-assuring. However, our data raise some
concerns as any drop in blood pressure, cardiac output, or
both in unstable PH patients could lead to hemodynamic
decompensation and even death due to right heart failure.
Such patients need to be studied further but our results at
least raise the possibility that non-invasive ventilation may
have deleterious hemodynamic consequences in patients
with advanced right heart failure.
Recently a multicenter, randomized controlled trial on
ASV therapy in patients with heart failure with reduced
left ventricular ejection fraction failed to show a statisti-
cally significant difference between patients randomized
to ASV therapy and those in the control group in the
primary endpoint of time to all-cause mortality or un-
planned hospitalization for worsening heart failure.
There was, however, a statistically significant increased
risk in all-cause and cardiovascular mortality in patients
receiving ASV therapy [21]. Whether our results, exem-
plifying potentially adverse hemodynamic effects of ASV
in patients with pre- or post-capillary PH can be trans-
ferred to this patient group and may help to explain
these results remains to be elucidated.
Our study has several strengths and limitations.
Strengths include the inclusion of well-characterized pa-
tients with severe pre-capillary and post-capillary PH,
the familiarization with ASV prior to right heart
catheterization and the fact that all patients had invasive
hemodynamic measurements. Limitations included the
single-center setting, the relatively small number of pa-
tients, the application of only one form of NIV, i.e. ASV,
and the limited duration of NIV. Different modes and
longer applications of NIV may result in different results
but we aimed to study the acute effects on NIV in these
patients and we wanted to make sure not to extend the
invasive procedure any longer than necessary. The pres-
sure support used in our study was relatively high com-
pared to other studies [17, 18] and our results may not
be fully applicable to lower pressure settings. In addition,
day-time measurements in awake patients may not ne-
cessarily provide the same results as night-time mea-
surements in asleep patients.
In conclusion, our data showed that administration of
NIV in stable patients with pre-capillary or post-
capillary PH resulted in small but consistent declines in
heart rate, systolic blood pressure, PAPm, PVR and car-
diac output. These hemodynamic effects were clinically
unapparent in the patients under study, but our findings
suggest that NIV should be used with caution in PH pa-
tients presenting with hypotension and low cardiac out-
put failure.
Table 4 Hemodynamic response to adaptive servoventilation in patients with post-capillary pulmonary hypertension (n = 12)
Baseline Intervention Recovery p*
Systolic blood pressure (mmHg) 133 ± 18 122 ± 23 133 ± 20 0.07
Diastolic blood pressure (mmHg) 71 ± 8 66 ± 13 69 ± 13 0.06
Heart rate (min−1) 73 ± 17 64 ± 17 68 ± 15 0.005
Right atrial pressure (mmHg) 13 ± 4 14 ± 4 13 ± 4 0.02
Mean pulmonary artery pressure (mmHg) 43 ± 9 37 ± 9 43 ± 9 <0.001
Pulmonary arterial wedge pressure (mmHg) 18 ± 3 21 ± 4 20 ± 2 0.16
Cardiac output (L/min) 4.4 ± 1.7 4.1 ± 1.4 4.3 ± 1.4 0.11
Cardiac index (L/min/m2) 2.3 ± 0.7 2.1 ± 0.6 2.3 ± 0.6 0.097
Stroke volume (ml/min) 64 ± 17 66 ± 19 65 ± 16 0.31
Pulmonary vascular resistance (dyn · s · cm−5) 495 ± 177 384 ± 190 458 ± 152 0.02
Peripheral oxygen saturation (%) 94 ± 2 95 ± 4 93 ± 4 0.29
Mixed venous oxygen saturation (%) 63 ± 6 65 ± 6 62 ± 7 0.02
Mixed venous pCO2 (mmHg) 42 ± 4 38 ± 6 41 ± 5 0.01
*Baseline versus intervention
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